Biomarker-based Immunoassays Market Size, Share and Growth Outlook, 2026

Biomarker-based Immunoassays Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biomarker-based Immunoassays Market size is forecast to increase from $6 Billion in 2026 to $9.14 Billion in 2034 at a CAGR of 5.4% between 2026 and 2034.

The Biomarker-based Immunoassays market report provides detailed analysis and outlook of Biomarker-based Immunoassays segments including By Technology (CLIA, ELISA, FIA, Multiplex & Microarray Immunoassays, Lateral Flow Immunoassay ), By Product & Service (Reagents & Kits, Analyzers & Instruments, Software & Services), By Specimen Type (Blood & Serum, Saliva, Urine, Cerebrospinal Fluid ), By End-User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Point-of-Care) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biomarker-based Immunoassays Industry Overview

Ultra-Sensitive Blood-Based Assays Transform Neurological Diagnostics

The Biomarker-based Immunoassays industry is undergoing rapid advancement as highly sensitive detection technologies enable the measurement of disease-associated biomarkers from minimally invasive blood samples. The ability to accurately detect low-abundance biomarkers is expanding the clinical utility of immunoassays across neurology, oncology, immunology, and chronic disease management. A notable development is the broad clinical availability of Quanterix Corporation’s LucentAD pTau-217 blood-based immunoassay, which operates on the company’s ultra-sensitive Simoa® platform. The assay targets phosphorylated tau-217, a key biomarker associated with Alzheimer’s disease pathology, and provides clinical-grade detection through a simple blood draw. This advancement supports earlier identification of neurodegenerative disease processes and assists healthcare providers in evaluating patient eligibility for newly approved amyloid-targeting therapies. The emergence of highly sensitive blood-based immunoassays is helping transform neurological diagnostics by reducing dependence on more invasive or resource-intensive diagnostic procedures.

Multiplex Immunoassays Enhance Biomarker Analysis Efficiency

Researchers and clinical laboratories are increasingly adopting multiplex immunoassay technologies capable of simultaneously measuring large numbers of biomarkers within a single sample. This approach improves laboratory efficiency, conserves sample volume, and enables more comprehensive biological profiling. Bio-Rad Laboratories expanded its biomarker-based immunoassay portfolio through the introduction of the Bio-Plex Pro Human Cytokine Screening Panel. The magnetic bead-based multiplex assay is engineered to quantify 48 inflammation-related biomarkers simultaneously within a single well. Such capabilities are particularly valuable for immunology research, vaccine development, inflammatory disease studies, and translational medicine applications where comprehensive cytokine profiling is essential. The growing use of multiplex immunoassays reflects increasing demand for high-content biomarker analysis platforms capable of generating broader biological insights while streamlining laboratory workflows and reducing testing complexity.

Automated Biomarker Monitoring Supports Chronic Disease Management

The Biomarker-based Immunoassays industry is also benefiting from increasing demand for automated diagnostic tools that support ongoing disease monitoring and treatment optimization. Roche Diagnostics achieved a significant milestone with the receipt of FDA Breakthrough Device Designation for its Elecsys NfL immunoassay designed for use on cobas® e analyzers. The blood-based assay measures neurofilament light chain biomarkers associated with neuroaxonal damage in patients with suspected Multiple Sclerosis. By providing an automated method for evaluating disease activity and therapeutic response, the immunoassay offers clinicians an additional tool for patient management beyond conventional imaging approaches such as magnetic resonance imaging. The development of automated biomarker-based immunoassays is expanding the role of laboratory diagnostics in chronic disease monitoring, enabling more frequent assessment of disease progression while supporting personalized treatment strategies across a broad range of neurological and inflammatory disorders.

Biomarker-based Immunoassays Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biomarker-based Immunoassays market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Roche (F. Hoffmann-La Roche), Abbott Laboratories, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, Siemens Healthineers, bioMérieux SA, Bio-Rad Laboratories, Sysmex Corporation, QuidelOrtho (Quidel Corporation), Becton, Dickinson and Company (BD). The Biomarker-based Immunoassays market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biomarker-based Immunoassays industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biomarker-based Immunoassays Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biomarker-based Immunoassays companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biomarker-based Immunoassays markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biomarker-based Immunoassays Market Competitive Benchmarking and Company Analysis

Leading companies in Biomarker-based Immunoassays industry include- Roche (F. Hoffmann-La Roche), Abbott Laboratories, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, Siemens Healthineers, bioMérieux SA, Bio-Rad Laboratories, Sysmex Corporation, QuidelOrtho (Quidel Corporation), Becton, Dickinson and Company (BD). The Biomarker-based Immunoassays market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biomarker-based Immunoassays Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biomarker-based Immunoassays market remains one of the strongest-performing segments in the country.
The US Biomarker-based Immunoassays Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biomarker-based Immunoassays market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biomarker-based Immunoassays industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biomarker-based Immunoassays markets

Canada's strong Biomarker-based Immunoassays sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biomarker-based Immunoassays market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biomarker-based Immunoassays Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biomarker-based Immunoassays market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biomarker-based Immunoassays population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biomarker-based Immunoassays industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biomarker-based Immunoassays market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biomarker-based Immunoassays sales through 2034

France Biomarker-based Immunoassays companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biomarker-based Immunoassays Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biomarker-based Immunoassays distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biomarker-based Immunoassays Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biomarker-based Immunoassays market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biomarker-based Immunoassays industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biomarker-based Immunoassays industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biomarker-based Immunoassays Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biomarker-based Immunoassays market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biomarker-based Immunoassays market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biomarker-based Immunoassays Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biomarker-based Immunoassays Market Segmentation

By Technology
CLIA
ELISA
FIA
Multiplex & Microarray Immunoassays
Lateral Flow Immunoassay
By Product & Service
Reagents & Kits
Analyzers & Instruments
Software & Services
By Specimen Type
Blood & Serum
Saliva
Urine
Cerebrospinal Fluid
By End-User
Clinical Laboratories
Hospitals
Pharmaceutical & Biotechnology Companies
Point-of-Care

Top Companies in Biomarker-based Immunoassays Industry

Roche (F. Hoffmann-La Roche)
Abbott Laboratories
Danaher Corporation (Beckman Coulter)
Thermo Fisher Scientific
Siemens Healthineers
bioMérieux SA
Bio-Rad Laboratories
Sysmex Corporation
QuidelOrtho (Quidel Corporation)
Becton, Dickinson and Company (BD)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025